

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Audited Standalone Financial Results for the Quarter and Year Ended 31st March 2022

PART I

(Rs. In Lakhs) except EPS

Sl.No	Particulars	3 months ended	Previous 3 months	Corresponding 3	For the Current	For the Previous Year
		(31-03-2022)	ended	months ended	Year	ended
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue From operations	1,498.24	2,046.01	2,184.05	8,514.03	7,121.79
II	Other Income	126.84	48.73	30.76	210.21	74.93
III	Total Income (I+II)	1,625.08	2,094.73	2,214.81	8,724.24	7,196.72
IV	EXPENSES					
a)	Cost of materials consumed	1,072.33	1,030.14	1,015.75	5,305.99	4,250.95
b)	Purchases of Stock-in-Trade	-	-	-	-	-
c)	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-107.52	207.77	248.64	(177.40)	294.60
d)	Employee benefits expense	371.06	363.46	392.17	1,450.39	1,198.41
e)	Finance costs	16.76	41.10	37.54	79.38	74.19
f)	Depreciation and amortization expenses	140.13	120.83	149.88	549.33	447.82
g)	Other expenses	214.69	161.15	107.24	785.79	348.07
	Total expenses (IV)	1,707.46	1,924.45	1,951.21	7,993.47	6,614.05
V	Profit/(loss) before exceptional items and tax (I-IV)	(82.38)	170.28	263.60	730.76	582.67
VI	Exceptional Items	19.12	-	-	215.65	-
VII	Profit/ (loss) before exceptions items and tax(V-VI)	(101.50)	170.28	263.60	515.11	582.67
	Tax expense:					
VIII	(1) Current tax	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	(101.50)	170.28	263.60	515.11	582.67
X	Profit/(loss) from discontinued operations	-	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)					
XIII	Profit/(loss) for the period (IX+XII)	(101.50)	170.28	263.60	515.11	582.67
	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss	10.66	-	-	(2.40)	-
XIV	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)Comprising Profit (Loss) and Other.comprehensive Income for the period)	(90.84)	170.28	263.60	512.71	582.67
	Earnings per equity share (for continuing operation):					
XVI	(1) Basic	(0.38)	0.72	1.11	2.17	2.46
	(2) Diluted	(0.38)	0.72	1.11	2.17	2.46
	Earnings per equity share (for discontinued operation):					
XVII	(1) Basic	-	-	-	-	-
	(2) Diluted	-	-	-	-	-
	Earning per equity share (for discontinued & continuing operation)					
XVIII	(1)Basic	(0.38)	0.72	1.11	2.17	2.46
	(2) Diluted	(0.38)	0.72	1.11	2.17	2.46

1. The above audited quarterly financial results and Year Ended 31.03.2022 were reviewed and recommended by the Audit Committee on 25.05.2022 and subsequently approved by the Board of Directors at their Meeting held on 26.05.2022

2. The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.

3. The above figures have been regrouped and Re-arranged Wherever considered necessary.

4. Being the Fourth Quarter of the year, Figures of the Quarter ended 31st March 2022 and Year to date for this Quarter are the balancing figures of the Year to date Figures.

5. The Company has provided the entire Gratuity liability as on 31st March 2022 in the books to the extent of Rs. 277.55 Lakhs, of which Rs.215.65 Lakhs pertains to the earlier years has been shown under Exceptional Items and Rs. 2.40 Lakhs which was gain /loss on actuarial Valuation has been shown under other Comprehensive Income and the Balance of Rs. 59.51 Lakhs has been charged during the year.

7. Company is upgrading its facility for capacity enhancement due to which the Plant was not fully operational resulting in decrease in revenue in the Current quarter.

Place: Chennai
Date: 26.05.2022

For BAFNA PHARMACEUTICALS LIMITED

(S. HEMALATHA)
Whole Time Director
DIN :02714329



BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Standalone Balance Sheet as on**(Rs. In Lakhs)**

Particulars	Stand Alone	
	As at 31st March 2022	As at 31 st March 2021
	Audited	Audited
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	3,884.56	3,596.64
(b) Capital Work-in-Progress		83.13
(c) Goodwill		
(d) Other Intangible Assets		
(e) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables		
(iii) Loans		
(iv) Other financial assets		
(g) Other Non-Current Assets		
Total Non-Current Assets	3,884.56	3,679.77
Current Assets		
(a) Inventories	2,028.05	1,544.34
(b) Financials Assets		
(i) Investments		
(ii) Trade Receivables	1,477.96	955.95
(iii) Cash and Cash Equivalents	17.30	180.37
(iv) Bank balance other than mentioned above		
(v) Loans		
(vi) Other financials assets		-
(c) Other Current Assets	1,616.57	2,286.16
(d) Assets classified as held for sale		
Total Current Assets	5,139.89	4,966.82
Total Assets (1+2)	9,024.44	8,646.59
EQUITY AND LIABILITIES		
(a) Equity Capital	2,365.63	2,365.63
(b) Other Equity	3,922.40	3,311.48
(c) Equity Share Warrants		
Equity Attributable to Equity Shareholders	6,288.04	5,677.11
(d) Non controlling Interests	-	-
Total Equity	6,288.04	5,677.11
Liabilities		
(a) Non-Current Liabilities		
(i) Financial Liabilities		



- Borrowings	789.20	250.00
- Trade Payable		
- Other Financial Liabilities	201.67	278.60
(ii) Provisions		
(iii) Deferred Tax Liabilities (Net)		
(iv) Other non-current liabilities	106.56	10.00
Total Non-Current Liabilities	1,097.42	538.60
(b) Current Liabilities		
(i) Financial Liabilities		
- Borrowings		
- Trade Payable	1,240.49	1,069.16
- Dues to micro and small enterprises		
- Dues to Others		
- Other Financial Liabilities	-	1,000.00
(ii) Other Current Liabilities	398.49	361.72
(iii) Provisions		
(iv) Current Tax Liabilities (net)		
Total Current Liabilities	1,638.98	2,430.87
Total Liabilities		
Total Equity and Liabilities	9,024.44	8,646.59

For BAFNA PHARMACEUTICALS LIMITED

Place : Chennai
Date : 26.05.2022



BAFNA PHARMACEUTICALS LTD		
STATEMENT OF CASH FLOW		
For the Year Ended 31st March 2022		
(All amounts in Rs.Lakhs)		
Particulars	As At 31st March 2022	As At 31st March 2021
Cash Flow from Operating Activities:		
Net Profit Before Tax and Exceptional Items	730.76	582.67
Adjustments for:		
Depreciation	549.33	447.82
Interest Paid	79.38	8.86
Interest Received	(4.46)	(3.95)
Sundry Balances Written back	-	(28.35)
Other Income	(204.92)	(41.90)
Lease Rent Received	(0.83)	(0.74)
Exceptional Item	(215.65)	-
Other Comprehensive Income	(2.40)	-
Operating Profit before Working Capital Changes	931.22	964.41
Adjustment For:		
[Increase]/decrease in Inventories	(483.72)	(403.09)
[Increase]/decrease in Trade Receivables	(522.01)	(352.47)
[Increase]/decrease in Short Term Loans and Advances	669.58	(1,290.82)
Increase/[decrease] in Trade Payables	171.33	(184.98)
Increase/[decrease] in Other Current Liabilities	36.77	(93.94)
Cash generated from Operation	803.18	(1,360.89)
Less: Tax Paid	-	-
Net Cash Used in Operating Activitiy (A)	803.18	(1,360.89)
Cash Flow from Investing Activities:		
Purchase of Fixed Assets	(754.11)	(609.47)
Changes in Long Term Loans and Advances		
Change in Other Non- Current Assets	-	-
Other Income	204.92	41.90
Interest Received	4.46	3.95
Sundry Balances Written back	-	28.35
Lease Rent received	0.83	0.74
Net Cash used in Investing Activities (B)	(543.90)	(534.54)
Cash Flow from Financing Activities		
Issue of Shares, Warrants & Application Activities	0	-
Proceeds of Investment Subsidy (State Govt Subsidy)	98.21	-
Changes in Long Term Borrowings	539.20	250.00
Changes in Short Term Borrowings	(980.37)	986.84
Interest Paid	(79.38)	(8.86)
Net Cash from Financing Activities (C)	(422.35)	1,227.98
Net Increase/ [Decrease] in Cash or Cash Equivalentents [A+B+C]	(163.07)	(667.64)
Opening Balance of Cash & Cash Equivalentents	180.37	848.01
Closing Balance of Cash & Cash Equivalentents	17.30	180.37

